Jump to main content
Jump to site search

Issue 8, 2020
Previous Article Next Article

Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures

Author affiliations

Abstract

We investigated the in vitro ultrasound-triggered delivery of paclitaxel, a well known anti-cancerous drug, encapsulated in an emulsion and in the presence of CT26 tumor cells. The emulsion was made of nanodroplets, whose volume comprised 95% perfluoro-octyl bromide and 5% tributyl O-acetylcitrate, in which paclitaxel was solubilized. These nanodroplets, prepared using a high-pressure microfluidizer, were stabilized by a tailor-made and recently patented biocompatible fluorinated surfactant. The delivery investigations were performed at 37 °C using a high intensity focused ultrasound transducer at a frequency of 1.1 MHz. The ultrasonic pulse was made of 275 sinusoidal periods and the pulse repetition frequency was 200 Hz with a duty cycle of 5%. The measured viabilities of CT26 cells showed that paclitaxel delivery was achievable for peak-to-peak pressures of 0.4 and 3.5 MPa, without having to vaporize the perfluorocarbon part of the droplet or to induce inertial cavitation.

Graphical abstract: Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures

Back to tab navigation

Article information


Submitted
05 Nov 2019
Accepted
22 Jan 2020
First published
29 Jan 2020

J. Mater. Chem. B, 2020,8, 1640-1648
Article type
Paper

Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures

N. Al Rifai, S. Desgranges, D. Le Guillou-Buffello, A. Giron, W. Urbach, M. Nassereddine, J. Charara, C. Contino-Pépin and N. Taulier, J. Mater. Chem. B, 2020, 8, 1640
DOI: 10.1039/C9TB02493J

Social activity

Search articles by author

Spotlight

Advertisements